Clinical trials: Hepatic Fibrosis
Metabolic Dysfunction-Associated Steatotic Liver Disease, Non-Alcoholic Fatty Liver Disease
Impact of Overt and Subclinical Hypothyroidism on Liver Fibrosis in Patients With MASLD
Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease (NAFLD), is one of the most common chronic liver conditions globally.
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease, Non-Alcoholic Fatty Liver Disease, Hypothyroidism, Liver Fibrosis
- Trial name
- NCT07827430
- Volunteers
- 120 people
- Sponsor
- Assiut University
Liver Fibrosis, Cirrhosis
Endosonographic Shear Wave Elastography to Assess Liver and Splenic Fibrosis
The study is being done to collect information on the effectiveness of endosonographic elastography (a technique which uses sound waves) to measure the stiffness of the liver and spleen.
- Trial name
- EUS SWE liver (NCT06867731)
- Testing
- Endosonographic Elastography, Endosonographic shear wave elastography
- Where
- United States
- Volunteers
- 124 people
- Sponsor
- Providence Medical Research Center
Nonalcoholic Fatty Liver Disease (NAFLD), Nonalcoholic Steatohepatitis (NASH)
Quantitative Ultrasound Techniques for Diagnosis of Nonalcoholic Steatohepatitis
Nonalcoholic fatty liver disease is the most common liver disease in Western countries, due in large part to its association with type 2 diabetes and obesity.
- Trial name
- QUS in NASH (NCT03572465)
- Testing
- Acoustic radiation force impulse (ARFI), magnetic resonance elastography (MRE)
- Where
- Canada
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Non-Alcoholic Fatty Liver Disease
Dynamic Changes and Risk Factors of Fibrosis and Steatosis Progression in Nonalcoholic Fatty Liver Disease
It is an observational study of non alcoholic fatty liver disease (NAFLD) patients with a calculated sample size of 500. Liver biopsy proved NAFLD patients will be recruited in this study for 10 years follow-up.
- Trial name
- NCT03635541
- Testing
- observational group of NAFLD
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Beijing Friendship Hospital
Liver Fibrosis, Liver Steatosis
The Sonic Incytes Liver Incyte System, Assessment of Liver Fibrosis and Steatosis
Evaluate the feasibility of the Liver Incyte system for liver elasticity measurement in healthy volunteers and patients with liver fibrosis.
- Trial name
- NCT03957070
- Testing
- Liver Incyte
- Where
- 2 sites in United States, Canada
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Sonic Incytes
End-Stage Liver Diseases
Human Umbilical Cord-mesenchymal Stem Cells Via Different Transplantation Routes in ESLD
Stem cells are non-terminal cells that can self renew and replicate through symmetric or asymmetric division, with the potential to differentiate into different types of cells and tissues.
- Trial name
- NCT06984497
- Testing
- Infusion of umbilical cord-mesenchymal stem cells through peripheral veins, Infusion of umbilical cord-mesenchymal stem cells through hepatic artery
- Where
- China
- Volunteers
- 32 people
- Sponsor
- General Hospital of Shenyang Military Region
Hepatic Impairment, Cirrhosis
Hepatic Impairment With Cirrhosis Due to Cholestatic Liver Disease
A Phase 1, Open-label Extension Groups Study in Subjects having Hepatic Impairment with Cirrhosis due to Cholestatic Liver Disease
- Conditions
- Hepatic Impairment, Cirrhosis, Cholestatic Liver Disease
- Trial name
- NCT05045482
- Testing
- Saroglitazar Magnesium 1 mg, Saroglitazar Magnesium 2 mg
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Zydus Therapeutics Inc.
Cirrhosis, Liver Failure
Empagliflozin in Patients With Cirrhosis and Ascites
A proof-of-concept placebo-controlled trial to explore the acute and 14-day effects of empagliflozin on natriuresis and total body water in patients with cirrhosis and ascites.
- Trial name
- EMPA Liver (NCT05726032)
- Testing
- Empagliflozin 10 MG
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Yale University
Portal Hypertension, Chronic Liver Disease (CLD)
EUS-guided Portal Pressure Gradient (PPG) Measurement: a Potential Alternative to the Traditional HVPG
The goal of this investigator-initiated, single-arm, prospective study is to evaluate the accuracy, safety, and feasibility of endoscopic ultrasound-guided portal pressure gradient (EUS-PPG) measurement as a potential alternative…
- Conditions
- Portal Hypertension, Chronic Liver Disease (CLD), Cirrhosis
- Trial name
- EUS-PPG (NCT06863012)
- Testing
- Endoscopic Ultrasound-Guided Portal Pressure Gradient (EUS-PPG) Measurement, Hepatic Venous Pressure Gradient (HVPG) Measurement
- Where
- Spain
- Volunteers
- 20 people
- Sponsor
- Fundacio Privada Mon Clinic Barcelona
MASH, MASH - Metabolic Dysfunction-Associated Steatohepatitis
Study of Resmetirom in Children and Adolescents With MASH
This study will evaluate the safety, pharmacokinetics (how the body absorbs, distributes, metabolizes, and eliminates the drug), and pharmacodynamics (how the drug affects the body) of resmetirom in children and adolescents with…
- Trial name
- NCT07763015
- Testing
- Resmetirom
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Madrigal Pharmaceuticals, Inc.
Lipid Profiles, Cirrhosis, Liver
Effect of LSD on Lipid Profiles Within 1 Year Postoperatively in Cirrhosis Patients With Portal Hypertension Bleeding
Patients with liver cirrhosis frequently exhibit dyslipidemia due to impaired hepatic lipid synthesis, altered bile acid metabolism, and portal hypertension.
- Conditions
- Lipid Profiles, Cirrhosis, Liver, Portal Hypertension, Splenectomy; Status
- Trial name
- LSD-LPPH (NCT07811700)
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Northern Jiangsu People's Hospital
Cirrhosis, Liver, Splenectomy; Status
Effect of LSD on Renal Function in Cirrhotic Patients With Portal Hypertension
Patients with liver cirrhosis and portal hypertension often have impaired kidney function due to reduced blood flow to the kidneys and fluid buildup in the abdomen (ascites).
- Conditions
- Cirrhosis, Liver, Splenectomy; Status, Renal Function Abnormal, Portal Hypertension
- Trial name
- NCT07811713
- Testing
- Laparoscopic splenectomy and azygoportal disconnection
- Volunteers
- 496 people
- Sponsor
- Northern Jiangsu People's Hospital
Cystic Fibrosis, Cystic Fibrosis Liver Disease
Real World Clinical Outcomes With Novel Modulator Therapy Combinations in People With CF (RECOVER)
RECOVER is a prospective, multicenter observational study designed to measure the real world clinical effectiveness of elexacaftor/tezacaftor/ivacaftor (ETI) triple combination therapy in people with cystic fibrosis initially…
- Conditions
- Cystic Fibrosis, Cystic Fibrosis Liver Disease, Cystic Fibrosis in Children, Adherence, Medication
- Trial name
- RECOVER (NCT04602468)
- Testing
- Elexacaftor/Tezacaftor/Ivacaftor
- Where
- 7 sites in Ireland, United Kingdom
- Volunteers
- 206 people
- Sponsor
- Royal College of Surgeons, Ireland
Hepatic Impairment, Cirrhosis
Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434
In this study, a single dose of VIR-2218 up to 200 mg SC or VIR-3434 at 300 mg SC monotherapy or a combination of VIR-2218 and VIR-3434 will be administered to assess the pharmacokinetic (PK) exposure, safety, and tolerability of…
- Trial name
- NCT05484206
- Testing
- VIR-2218, VIR-3434
- Where
- 4 sites in United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Vir Biotechnology, Inc.
Biliary Atresia, Kasai Operation
Umbilical Cord Mesenchymal Stem Cell Therapy for Biliary Atresia
Biliary atresia is a progressive liver disease in infants where liver transplantation is often the only long-term option once cirrhosis develops.
- Conditions
- Biliary Atresia, Kasai Operation, Liver Fibrosis, Stem Cell
- Trial name
- NCT07797673
- Testing
- Umbilical Cord-Mesenchymal Stem Cells (UC-MSC), Kasai Portoenterostomy
- Where
- Indonesia
- Volunteers
- 40 people
- Sponsor
- Dr Cipto Mangunkusumo General Hospital
Cirrhosis, Ascites Hepatic
Using Bedside Ultrasound to Understand Fluid Management in Patients With Chronic Liver Disease
The goal of this observational study is to see if repeated bedside ultrasound measurements of the lungs and abdomen as well as a blood vessel in the neck can be done in patients with advanced liver disease and ascites (fluid in…
- Conditions
- Cirrhosis, Ascites Hepatic, Fluid Balance
- Trial name
- POCUS-C (NCT07810855)
- Testing
- Ultrasound measurement, Blood draw for the laboratory assessment
- Volunteers
- 100 people
- Sponsor
- Royal Free Hospital NHS Foundation Trust
Chronic Liver Disease and Cirrhosis
Impact of Home-Based Aerobic and Resistance Training in Chronic Liver Disease: a Randomized Control Trial
The goal of this clinical trial is to evaluate whether home-based exercise interventions, including aerobic exercise (AE) and a combination of aerobic and resistance exercise (ARE), can improve physical and health-related…
- Trial name
- NCT06892366
- Testing
- Home-Based Aerobic Exercise Program, Home-Based Aerobic and Resistance Exercise (ARE) Group
- Where
- Turkey (Türkiye)
- Volunteers
- 39 people
- Sponsor
- Hacettepe University
Cirrhoses, Liver, Decompensated Cirrhosis of Liver
Role of Allopurinol in Prevention of Complications Related to Decompensated Cirrhosis of Liver
Cirrhosis, a leading cause of global mortality, progresses to life-threatening complications like ascites, hepatic encephalopathy, and hepatorenal syndrome.
- Trial name
- NCT07800598
- Testing
- Allopurinol Tablet
- Where
- 2 sites in Bangladesh
- Volunteers
- 54 people
- Sponsor
- Bangladesh Medical University
Cirrhosis, Portal Hypertension
Body-weight Reduction Effect on Portal Hypertension in Compensated Cirrhosis
Obesity and metabolic abnormalities accelerate decompensation in compensated cirrhosis, driven by clinically significant portal hypertension (CSPH, HVPG≥10 mmHg).
- Conditions
- Cirrhosis, Portal Hypertension, Fatty Liver Disease, GLP-1
- Trial name
- B-REACH (NCT07797101)
- Testing
- Mazdutide injection
- Volunteers
- 50 people
- Sponsor
- The Second Affiliated Hospital of Chongqing Medical University
Hepatic Steato-Fibrosis, Non-Alcoholic Fatty Liver Disease
MASLD in Primary Hypothyroidism and Efficacy of Dapaglifozin
Non-alcoholic fatty liver disease (NAFLD) is a global epidemic with a prevalence of 25-40%.Primary Hypothyroidism is one of Endocrinopathies who are at risk of developing NAFLD/NASH and estimated prevalence of Primary…
- Trial name
- SHIELD (NCT06373523)
- Testing
- Dapagliflozin 10mg Tab, Levothyroxine Replacement daily
- Where
- India
- Volunteers
- 50 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh